GABRIELA BOUFELLI DE FREITAS

(Fonte: Lattes)
Índice h a partir de 2011
3
Lattes
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/58 - Laboratório de Ginecologia Estrutural e Molecular, Hospital das Clínicas, Faculdade de Medicina

Filtros

Limpar filtros

Configurações

Autor: MAESAKA, Jonathan Yugo ×

Resultados de Busca

Agora exibindo 1 - 4 de 4
  • bookPart
    Doenças Benignas da Mama
    (2016) RUIZ, Carlos Alberto; PIATO, José Roberto Morales; MAESAKA, Jonathan Yugo; FREITAS, Gabriela Boufelli de; RICCI, Marcos Desidério; FILASSI, José Roberto
  • conferenceObject
    Does conservative surgery treatment for locally advanced breast cancer safe after neoadjuvant treatment?
    (2018) BOUFELLI, Gabriela; MOTA, Bruna Salani; FRANCA, Flavia Cardoso; DORIA, Maira Teixeira; MAESAKA, Jonathan Yugo; RICCI, Marcos Desiderio; PIATO, Jose Roberto Morales; ROCHA, Fernanda Barbosa Coelho; GIRIBELA, Aricia Helena Galvao; GONCALVES, Rodrigo; MASILI-OKU, Sergio; MANO, Max Senna; CHALA, Luciano Fernandes; THOMPSON, Bruna Maria; BARACAT, Edmund Chada; FILASSI, Jose Roberto
  • article 1 Citação(ões) na Scopus
    Measurement of extracapsular extension in sentinel lymph node as a possible predictor of residual axillary disease in breast cancer
    (2023) FREITAS, Gabriela Boufelli de; MOTA, Bruna Salani; MAESAKA, Jonathan Yugo; PINHEIRO, Cintia Cardoso; LIMA, Luiz Guilherme Cernaglia Aureliano de; JR, Jose Maria Soares; BARACAT, Edmund Chada; FILASSI, Jose Roberto
    Background: The presence of Extracapsular Extension (ECE) in the Sentinel Lymph Node Biopsy (SLNB) is still a doubt in the literature. Some studies suggest that the presence of ECE may be related to a greater number of posi-tive axillary lymph nodes which could impact Disease Free Survival (DFS) and Overall Survival (OS). This study searches for the clinical significance of the ECE. Methods: Retrospective cohort comparing the presence or absence of ECE in T1-2 invasive breast cancer with posi-tive SLNB. All cases treated surgically at the Cancer Institute of the State of Sa not similar to o Paulo (ICESP) between 2009 and 2013 were analyzed. All patients with axillary disease in SLNB underwent AD.Outcomes: Identify the association between the presence and length of ECE and additional axillary positive lymph nodes, OS and DFS between both groups. Results: 128 patients with positive SLNB were included, and 65 had ECE. The mean metastasis size of 0.62 (SD = 0.59) mm at SLNB was related to the presence of ECE (p < 0.008). The presence of ECE was related to a higher mean of positive sentinel lymph nodes, 3.9 (+/- 4.8) vs. 2.0 (+/- 2.1), p = 0.001. The median length of fol-low-up was 115 months. The OS and DFS rates had no differences between the groups. Conclusion:The presence of ECE was associated with additional positive axillary lymph nodes in this study. There-fore, the OS and DFS were similar in both groups after 10 years of follow-up. It is necessary for additional studies to define the importance of AD when SLNB with ECE.
  • article 0 Citação(ões) na Scopus
    Locally advanced breast cancer: breast-conserving surgery and other factors linked to overall survival after neoadjuvant treatment
    (2023) NOBREGA, Gabriela Bezerra; MOTA, Bruna Salani; FREITAS, Gabriela Boufelli de; MAESAKA, Jonathan Yugo; MOTA, Rosa Maria Salani; GONCALVES, Rodrigo; TRINCONI, Angela Francisca; RICCI, Marcos Desiderio; PIATO, Jose Roberto; SOARES-JR, Jose Maria; BARACAT, Edmund Chada; FILASSI, Jose Roberto
    Background Recent data suggest that breast-conserving surgery (BCS) may positively impact overall survival (OS) in early breast cancer. However, the role of BCS in locally advanced breast cancer (LABC) following neoadjuvant therapy (NAT) remains uncertain.Methods We conducted a retrospective cohort study involving 530 LABC patients who underwent surgery after NAT between 2010 and 2015. Outcomes examined included OS, distant recurrence rates (DRR), and loco-regional recurrence rates (LRRs).Results Among the 927 breast cancer patients who received NAT, 530 were eligible for our study. Of these, 24.6% underwent BCS, while 75.4% underwent mastectomy (MS). The median follow-up duration was 79 months. BCS patients exhibited a higher pathological complete response (PCR) rate compared to those who underwent MS (22.3% vs. 10%, p < 0.001). The 6-year OS rates for BCS and MS were 81.5% and 62%, respectively (p < 0.000). In multivariate OS analysis, MS was associated with worse outcomes (OR 1.678; 95% CI 1.069-2.635; p = 0.024), as was body mass index (BMI) (OR 1.031; 95% CI 1.006-1.058; p = 0.017), and stage IIIB or IIIC (OR 2.450; 95% CI 1.561-3.846; p < 0.000). Conversely, PCR (OR 0.42; 95% CI 0.220-0.801; p = 0.008) was associated with improved survival. DRR was significantly lower in BCS (15.4%) compared to MS (36.8%) (OR 0.298; 95% CI 0.177-0.504). LRRs were comparable between BCS (9.2%) and MS (9.5%) (OR 0.693; 95% CI 0.347-1.383).Conclusion Our findings suggest that BCS is oncologically safe, even for patients with large lesions, and is associated with superior OS rates compared to MS. Additionally, lower BMI, lower pretreatment stage, and achieving PCR were associated with improved survival outcomes.